Literature DB >> 31140130

Diffuse large B cell lymphoma secondary to JC virus in progressive multifocal leukoencephalopathy.

Ashwin Reddi1, Nikhil Patel2, Nicholas A Morris3.   

Abstract

We present the case of a 43-year-old-man with a past medical history of HIV with recently initiated HAART and existing PML that presented with altered mental status. The initial diagnosis was deemed to be PML-IRIS; however, neuroimaging brought into question this diagnosis. Flow cytometry performed from the cerebrospinal fluid revealed diffuse large B cell lymphoma. JC virus may act in an oncogenic role similarly to EBV and predispose to CNS lymphomas. Patients with PML caused by JC virus may develop secondary malignancies.

Entities:  

Keywords:  Diffuse large B cell lymphoma; EBV; IRIS; JC virus; Malignancy; PML

Year:  2019        PMID： 31140130     DOI： 10.1007/s13365-019-00760-z

Source DB:  PubMed          Journal:  J Neurovirol        ISSN： 1355-0284            Impact factor:   2.643


  20 in total

Review 1.  Imaging manifestations of progressive multifocal leukoencephalopathy.

Authors:  R Shah; A K Bag; P R Chapman; J K Curé
Journal:  Clin Radiol       Date:  2010-06       Impact factor: 2.350

Review 2.  Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis.

Authors:  Chen S Tan; Igor J Koralnik
Journal:  Lancet Neurol       Date:  2010-04       Impact factor: 44.182

3.  JC virus binds to primary human glial cells, tonsillar stromal cells, and B-lymphocytes, but not to T lymphocytes.

Authors:  G Wei; C K Liu; W J Atwood
Journal:  J Neurovirol       Date:  2000-04       Impact factor: 2.643

4.  Detection of human neurotropic JC virus DNA sequence and expression of the viral oncogenic protein in pediatric medulloblastomas.

Authors:  B Krynska; L Del Valle; S Croul; J Gordon; C D Katsetos; M Carbone; A Giordano; K Khalili
Journal:  Proc Natl Acad Sci U S A       Date:  1999-09-28       Impact factor: 11.205

5.  Clinical epidemiology and survival of progressive multifocal leukoencephalopathy in the era of highly active antiretroviral therapy: data from the Italian Registry Investigative Neuro AIDS (IRINA).

Authors:  Andrea Antinori; Antonella Cingolani; Patrizia Lorenzini; Maria Letizia Giancola; Ilaria Uccella; Simona Bossolasco; Susanna Grisetti; Francesca Moretti; Beniamino Vigo; Marco Bongiovanni; Bruno Del Grosso; Maria Irene Arcidiacono; Giovanni Carlo Fibbia; Maurizio Mena; Maria Grazia Finazzi; Giovanni Guaraldi; Adriana Ammassari; Antonella d'Arminio Monforte; Paola Cinque; Andrea De Luca
Journal:  J Neurovirol       Date:  2003       Impact factor: 2.643

6.  Human polyomavirus JC (JCV) infection of human B lymphocytes: a possible mechanism for JCV transmigration across the blood-brain barrier.

Authors:  Moti L Chapagain; Vivek R Nerurkar
Journal:  J Infect Dis       Date:  2010-07-15       Impact factor: 5.226

7.  Pathology of immune reconstitution inflammatory syndrome in multiple sclerosis with natalizumab-associated progressive multifocal leukoencephalopathy.

Authors:  Imke Metz; Ernst-Wilhelm Radue; Agustin Oterino; Tania Kümpfel; Heinz Wiendl; Sven Schippling; Jens Kuhle; Mohammad Ali Sahraian; Francoise Gray; Veronika Jakl; Darius Häusler; Wolfgang Brück
Journal:  Acta Neuropathol       Date:  2011-11-06       Impact factor: 17.088

Review 8.  EBV-Positive Lymphoproliferations of B- T- and NK-Cell Derivation in Non-Immunocompromised Hosts.

Authors:  Stefan D Dojcinov; Falko Fend; Leticia Quintanilla-Martinez
Journal:  Pathogens       Date:  2018-03-07

9.  Incidence and risk factors for immune reconstitution inflammatory syndrome in an ethnically diverse HIV type 1-infected cohort.

Authors:  I Ratnam; C Chiu; N-B Kandala; P J Easterbrook
Journal:  Clin Infect Dis       Date:  2005-12-28       Impact factor: 9.079

10.  Primary bilateral adrenal B-cell lymphoma associated with EBV and JCV infection.

Authors:  Luisa Barzon; Marta Trevisan; Filippo Marino; Vincenza Guzzardo; Giorgio Palù
Journal:  Infect Agent Cancer       Date:  2009-01-15       Impact factor: 2.965
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.